FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Biblioteca de Stacks

Skin Glow & Hair Density

Skin & Hairintermediate
37
Share
Péptidos

3

Promedio Diario mcg

3,250

Nivel

intermediate

Añadido

May 16, 2026

Visión General

The Skin Glow and Hair Density stack is an intermediate-level aesthetic protocol that targets the biological mechanisms underlying skin radiance, elasticity, and hair follicle vitality. Rather than masking cosmetic concerns topically, this stack works at the cellular level to restore youthful gene expression patterns and promote robust collagen and keratin production. GHK-Cu, administered at 500mcg daily, is the primary driver of visible skin and hair improvements in this protocol. This naturally occurring copper peptide declines significantly with age and has been shown in research to reset gene expression in fibroblasts to a more youthful pattern. It stimulates collagen I, III, and V synthesis, increases elastin production, promotes glycosaminoglycan synthesis for improved skin hydration, and enhances hair follicle size and proliferative capacity. Studies have demonstrated GHK-Cu can increase hair follicle cell proliferation by up to 70 percent while simultaneously improving skin thickness and firmness. Epithalon, dosed at 5000mcg every other day, addresses skin and hair aging at the chromosomal level by activating telomerase in somatic cells. As cells divide throughout life, telomere shortening signals senescence, causing visible aging of skin and hair. Epithalon counteracts this by maintaining telomere length, effectively extending the replicative lifespan of dermal fibroblasts, keratinocytes, and hair follicle stem cells. Research in cell culture models has shown telomerase activation can reverse markers of cellular aging, translating to improved skin texture and hair growth cycles. BPC-157 at 250mcg daily supports the stack by enhancing blood vessel formation in the dermis and scalp. Improved microcirculation delivers more oxygen and nutrients to skin cells and hair follicles, creating optimal conditions for the regenerative effects of GHK-Cu and Epithalon to manifest visibly. This protocol is suited for individuals experiencing age-related skin thinning, loss of radiance, fine lines, or diffuse hair thinning. It works best as an 8-12 week cycle with visible improvements typically appearing by weeks 4-6. Morning administration of all peptides is recommended. For enhanced results, pair with adequate protein intake, vitamin C supplementation, and sun protection.

Protocolo de Dosis

500 mcg

por dosis

Epithalon

Every other day

Leer más sobre Epithalon →

5,000 mcg

por dosis

250 mcg

por dosis

Objetivos & Evidencia

Nivel de evidencia:community

Comments

Sign in to join the discussion

Aviso: Este stack es subido por la comunidad y solo tiene fines de investigación. Peptide Contacts no verifica la seguridad o eficacia de los stacks subidos. Siempre consulte a un profesional de la salud calificado antes de usar cualquier protocolo de péptidos.